附近上门

, creating oncology drugs intended to provide precision oncology options, closed on an additional $36 million to bring its Series B financing round to a total of $236 million, the company said Monday.

Subscribe to the 附近上门 Daily

New investors to the round included and , the company said in a . The San Diego-based company began raising its Series B back in April with a $200 million round. That round was led by and, and included participation from new investors, and.

Including the new funding, Erasca has raised a total of $300 million since the company鈥檚 inception in 2018.

Erasca, which draws its name from 鈥渆rase cancer,鈥� will use the funding to 鈥渢o support the clinical development of multiple promising oncology programs, continue driving corporate development efforts and further advance the company鈥檚 in-house drug discovery pipeline,鈥� the company said. It isn鈥檛 clear which types of cancer the company is developing treatments for.

This is Partner Fund Management鈥檚 , according to 附近上门 data. It also invested in companies addressing various aspects of the health care industry, including , and . Meanwhile, OrbiMed has made 29 investments, according to 附近上门 data. That includes eight investments in August, the most recent , another startup fighting difficult-to-treat cancers, which raised a $98 million Series C last week.

Illustration: